Alternative pathway activation involving EGFR, KRAS, KIT, ERBB, MET and IGF-1R are also responsible for ALK+ tumor crizotinib resistance
Alternative pathway activation involving EGFR, KRAS, KIT, ERBB, MET and IGF-1R are also responsible for ALK+ tumor crizotinib resistance. were produced and adjusted for specific binding and function. Proteins containing…